1.37
+0.01(+0.74%)
Currency In USD
| Previous Close | 1.36 |
| Open | 1.36 |
| Day High | 1.37 |
| Day Low | 1.3 |
| 52-Week High | 4.39 |
| 52-Week Low | 0.99 |
| Volume | 526,997 |
| Average Volume | 783,870 |
| Market Cap | 86.59M |
| PE | -2.4 |
| EPS | -0.57 |
| Moving Average 50 Days | 1.7 |
| Moving Average 200 Days | 1.76 |
| Change | 0.01 |
If you invested $1000 in MacroGenics, Inc. (MGNX) 10 years ago, it would be worth $40.85 as of November 10, 2025 at a share price of $1.37. Whereas If you bought $1000 worth of MacroGenics, Inc. (MGNX) shares 5 years ago, it would be worth $64.59 as of November 10, 2025 at a share price of $1.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
GlobeNewswire Inc.
Nov 06, 2025 9:30 PM GMT
ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 8:30 PM GMT
ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ President &
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
GlobeNewswire Inc.
Aug 13, 2025 8:01 PM GMT
ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August